Verona Pharma Quote - VRNA | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Verona Pharma Plc (VRNA) Share Price

Verona Pharma Plc (VRNA)

35.66

0.29

(0.82%)

At close: 18 November 8:00AM

Delayed by 15 minutes

34.90

-0.76

( -2.13% )

After Hours: 11:37AM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

34.90

Bid

31.00

Offer

35.66

Volume

988,179

34.7104 Day's Range 35.965

0.00 52 Week Range 0.00

Market Cap

Previous Close

35.37

Open

35.01

Last Trade

Last Trade Time

10:50:36

Financial Volume

US$ 34,861,954

VWAP

35.279

Average Volume (3m)

-

Shares Outstanding

81,831,170

Dividend Yield

-

PE Ratio

0.00

Earnings Per Share (EPS)

-

Revenue

-

Net Profit

-54.37M

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which ... Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.veronapharma.com

Headquarters

London, Gbr

Founded

-

Verona Pharma Plc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VRNA. The last closing price for Verona Pharma was US$35.37. Over the last year, Verona Pharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Verona Pharma currently has 81,831,170 shares in issue. The market capitalisation of Verona Pharma is US$2.89 billion.

Overall Flow

Bullish

Net Premium

26k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Verona Pharma to Present at Jefferies London Healthcare Conference

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third...

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and two posters on analyses...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SMCXDefiance Daily Target 2X Long SMCI ETF	US$ 1.31 (33.67%)	3.01M
MONDMondee Holdings Inc	US$ 1.45 (26.09%)	2.4k
ATRAAtara Biotherapeutics Inc	US$ 14.26 (18.83%)	328
AIRGAirgain Inc	US$ 10.94 (17.01%)	1.15k
SMCISuper Micro Computer Inc	US$ 21.68 (16.68%)	9.83M
FLYEFly E Group Inc	US$ 0.525 (-23.84%)	599.57k
QATiShares Trust iShares MSCI Qatar	US$ 14.80 (-19.13%)	100
ABPAbpro Holdings Inc	US$ 3.07 (-17.25%)	324
BENFBeneficient	US$ 0.9999 (-16.68%)	773.1k
TRUGTruGolf Holdings Inc	US$ 0.4111 (-14.34%)	7.45k
ELABElevai Labs Inc	US$ 0.0214 (-3.17%)	26.05M
SMCISuper Micro Computer Inc	US$ 21.68 (16.68%)	9.83M
IOVAIovance Biotherapeutics Inc	US$ 8.30 (1.47%)	8.85M
CEROCERo Therapeutics Holdings Inc	US$ 0.261 (-8.52%)	7.74M
HOODRobinhood Markets Inc	US$ 32.60 (0.87%)	6.82M

Hoskuld

Hoskuld 2 days ago

Right - if SOC then this blows up in a good way.

powerwalker

powerwalker 3 days ago

On November 19th, possibly updates on scripts//sales ...

Verona Pharma to Present at Jefferies London Healthcare Conference

https://finance.yahoo.com/news/verona-pharma-present-jefferies-london-070000088.html

powerwalker

powerwalker 3 days ago

Hoskuld, any thing new on the scripts? Tough day yesterday.

MegaPirate61

MegaPirate61 4 days ago

I'm seeing a lot of soc references in the commentary from the analysts and physicians networks. If that happens in asthma and copd it's 20 billion per month. Obviously that's a long shot but it's possible in 10 yrs. That's the scary thing.

Hoskuld

Hoskuld 5 days ago

LOL I like your sign off! I don't think most COPD patients will switch to ohtuvayre but will just add Oh (steroids are pretty cheap.) Add 250,000 bronchiectasis patients to probably 1.5m COPD patients and those add up to some immense numbers. Maybe I lack imagination, but I don't think $100b is in the cards - maybe $20b if every single thing goes well.

MegaPirate61

MegaPirate61 1 week ago

New valuation of vrna at 218 per share per takeover advocate specialist Caligan.

https://www.cnbc.com/2024/11/09/caligan-takes-a-stake-in-verona-pharma-sees-opportunity-to-generate-more-value.html

I personally feel this estimate is way low. If a big part 4 million copd patients on steroids are switched over to ohtuvayre as fda is pushing, plus other combos in a progressive disease scenario (meaning eventually all copd patients will need something else to supplement their therapy) you're looking at 3300 per 3 month supply or 13 billion per quarter. Double that for the 1 million fibrosis patients plus asthmatic patients once approved, and that's 100 bil per yr + without international or other label expansion. Fairly safe to say it's a 250 billion dollar asset in 10 yrs all imo.

I'd put fair value at 2000 per share minimum. But what do I know I'm just a pirate. Ohtuvayrrrg!

Hoskuld

Hoskuld 1 week ago

And scripts are trending up in a big way - recently they have been doubling every 4 weeks.

MegaPirate61

MegaPirate61 1 week ago

Insider purchases that appear to be about 200 grand worth, possible exercises of options but marked as acquired nov 6

powerwalker

powerwalker 1 week ago

Why the pop over the last 90 minutes or so?

Hoskuld

Hoskuld 2 weeks ago

Hi PW! Scripts will just tell us the trend - which is strong right now - but cannot give us the absolute #s...which are about 2.5x-3x the IMS script data. I think the company would consider a buyout at the right price - IMO $100 right now would be OK based on the trend and the upside is huge from there.

powerwalker

powerwalker 2 weeks ago

Thank you for your reply.

As to 1), will we learn of those higher revenues directly from Verona or indirectly via the weekly script info?

For 2), are the company's actions geared towards a take-out soon or later when more revenue sources are likely? or, will Glaxo and AZ jump the gun and go after Verona now that revenue is coming in strong for a sensational product?

Once again, thank you, Hoskuld.

Hoskuld

Hoskuld 2 weeks ago

I think there are 2 catalysts:

1. The continuous catalyst of higher and higher revenues and

2. Acquisition by Glaxo or AstraZeneca etc.

It will take a while for Bronchiectasis trial results but those will help, too.

powerwalker

powerwalker 2 weeks ago

Hoskuld, thanks for your post, to which I agree. What are the next catalysts for the stock ... or we wait until next year for Q4 and total 2024 numbers?

TYIA

Hoskuld

Hoskuld 2 weeks ago

Hi Powerwalker. These were great results. The actually scripts are much much higher than the IMS scripts indicate. This is trending to be a blockbuster by the end of next year. VRNA is going to be one of those big winners - and because it is now backed up by revenue, it is far less risky now from a PPS pov.

powerwalker

powerwalker 2 weeks ago

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

https://finance.yahoo.com/news/verona-pharma-reports-third-quarter-070000243.html

One has to like that October sales were HIGHER than Q3's.

powerwalker

powerwalker 2 weeks ago

Hoskuld, have you seen any numbers?

TYIA

MegaPirate61

MegaPirate61 2 weeks ago

All my best to you Roger. Noticed the earnings which is always on thursdays is now on Monday. Can't help but wonder if Ligand wants a bigger stake than just low single digit royalty on ohtuvayre. Though a takeout by azn is possible I think ligand all stock deal or 5 to 10% buy in is far more likely.

powerwalker

powerwalker 2 weeks ago

Roger, that will be great. God bless you and your family. Hopefully, you are among the new script numbers for next week.

Roger1

Roger1 2 weeks ago

Hopefully next week. Thanks for asking.

powerwalker

powerwalker 2 weeks ago

Roger, thank you for the article. How is your pursuit to utilize ensifentrine going?

Roger1

Roger1 2 weeks ago

https://share.newsbreak.com/9lxcziaz

Happy to see this.

powerwalker

powerwalker 3 weeks ago

Thank you, Hoskuld. Looking forward to next Monday, November 4th.

MegaPirate61

MegaPirate61 3 weeks ago

Did we know the next weekly oct 18 script info yet?

Hoskuld

Hoskuld 3 weeks ago

Sometimes it is difficult to say what option trades indicate - options are often part of hedging strategies. I am bullish on VRNA but these options sales/purchases could signify different expectations or similar expectations...who knows?

powerwalker

powerwalker 3 weeks ago

It looks as if someone (not me) is interested in the March 2025 $30 calls. There were 90 contracts traded yesterday and 40 today. Hope the buyer is right!

Hoskuld

Hoskuld 4 weeks ago

We should have 10/18 and 10/24 script data by then...

powerwalker

powerwalker 4 weeks ago

Thank you, Hoskuld.

Verona cc on 11/4 with Q3 stats ... hopefully, it is a good sign being first thing on a Monday morning. They are anxious to talk!

Hoskuld

Hoskuld 4 weeks ago

Yes - 324 week ending 10/11

powerwalker

powerwalker 4 weeks ago

Hoskuld, does that mean the scripts are over 300? Higher?

TYIA

Hoskuld

Hoskuld 4 weeks ago

Scripts are trending up strongly now - more than 3x 4 weeks ago.

Hoskuld

Hoskuld 1 month ago

IMO $70-$100 by the end of 2025.

powerwalker

powerwalker 1 month ago

All the best, Roger.

I sent message via its web site over the weekend asking about Marketing here in the States. I'll let you know when I hear back from them.

Roger1

Roger1 1 month ago

Still in process of getting it. Delay is on my end with my Dr. Should be resolved next month with new doc. I can tell you that Verona reached out to me almost immediately after my inquiry in August and have texted and emailed since. They have been very responsive. Very positive feelings about this company.

powerwalker

powerwalker 1 month ago

So, Roger, are you using Ohtuvayre? If so, is it meeting your expectations? TYIA

Roger1

Roger1 1 month ago

Acaria Health is one of the fulfillment pharmacies. They are handling me.

powerwalker

powerwalker 1 month ago

Roger, Hoskuld has access to such data but did not specify the numbers. See post #214.

Roger1

Roger1 1 month ago

Do. you have a link to your info by any chance? Release, conference, etc? TIA

powerwalker

powerwalker 1 month ago

Thank you, Hoskuld, for the information.

Do you have any numbers to share ... and get some people excited. TYIA

Hoskuld

Hoskuld 1 month ago

Prescription fulfillment is finally accelerating. Buckle up.

👍️ 1 👏 1

Hoskuld

Hoskuld 2 months ago

That is great GB!

gbrown6332

gbrown6332 2 months ago

Saw your original post on VRNA. Sounded good. Decided to tag along. Glad I did.

Thks,

G. Brown

powerwalker

powerwalker 3 months ago

Someone certainly does not want this stock to go and stay above $28.

Hoskuld

Hoskuld 3 months ago

Got it - you meant pharmacies not pharmas (which are drug manufacturing companies.) Makes sense. I will actually check to see if ohtuvayre is at local CVS this week!

I can imagine you would be excited about this and I am really looking forward to hearing about your experience with it! Thanks for sharing!

Roger1

Roger1 3 months ago

Btw, I didn't say it wasn't going well. I said it takes time for any new drug given the logistics. I think they're doing a great job or i wouldn't have invested in them.

Roger1

Roger1 3 months ago

Checked out the drug with CVS and was told about specialty pharmas. I'm a COPD patient and respiratory therapist and have followed trials for quite a while and am delighted to try this drug. Was told the same thing by Verona when I signed up for the drug through the patient portal. I used to teach the mechanism of action of bronchodilators. Specifically C3-5AMP . Taught therapists, nurses, and many of the older physicians sat in for refresher.
Check with your pharmacist and see if it's available. I'd be interested in your findings.

Hoskuld

Hoskuld 3 months ago

They were already detailing 100 of the top 2,500 pulmonologists as of 2 weeks ago, and presumably are detailing ~20-25 more each week. The launch is already going well.

What did you mean by "speciality pharmas until then"?

Roger1

Roger1 3 months ago

I think it will be January b4 the roll out is complete. Specialty pharmas until then. Have patience, this drug will be a blockbuster with its double mechanism of action.

Hoskuld

Hoskuld 3 months ago

Hi PW - the company has said that they are looking to partner ohtuvayre in the EU and, as a part of that partnership, the partner would be responsible for developing an inhaler for ohtuvayre, too.

I agree that the company management seems sharp. And all newly launched products have issues - let's hope Verona is on top of the issues. I wrote IR and simply asked that they send me a note saying that my message was received and the responsible people at Verona are "on it".

powerwalker

powerwalker 3 months ago

Hoskuld, I listened to the quarterly cc and the Canaccord Genuity presentation and I came away with the impression that Verona management is on top of all matters: marketing, sales, and distribution. If there were a problem, it might be the pharmacies listing Ohtuvayre in their systems, given it is a new product and it needs to establish an ordering pattern for it.

Hoping the patient numbers are higher within a year.

Have you seen or heard any info on EMA and/or UK filings/approval?

Hoskuld

Hoskuld 3 months ago

Just following up on this...I can see ohtuvayre being the SOC. I think this will grow very, very swiftly.

🎯 1 👍️ 1

National Storage Affilia...

L3Harris Technologies

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions